Navigation Links
ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Date:11/16/2007

and Navelbine. Determining the safety of a single dose of ANX-530 was a secondary objective. In the first week, patients were dosed with either ANX-530 or Navelbine, and after a washout period, were dosed with the opposite drug during the second week of treatment. The FDA has indicated that this single clinical study, should it demonstrate pharmacokinetic equivalence between ANX-530 and Navelbine, would provide sufficient clinical data to support a Section 505(b)(2) NDA.

Pharmacokinetic equivalence was determined based on federal regulations and FDA guidance regarding bioequivalence studies. If the upper and lower bounds of the AUC ratio's and the Cmax ratio's 90% confidence interval ranged from 0.80 to 1.25, ANX-530 and Navelbine were considered to have equivalent pharmacokinetics. AUC is a measure of the total amount of the drug circulating in the body over time. Cmax is the maximum concentration of the drug measured in the blood at any given time. The results of a clinical study are actually estimates of what might be expected if the treatment were to be given to the entire population of interest. Confidence intervals indicate the precision of such an estimate. Pursuant to the study's protocol and statistical analysis plan, data from all 31 patients who received both study drugs were included in the analysis.

About ANX-530 (vinorelbine emulsion)

ANX-530 is a novel emulsion formulation of vinorelbine tartrate, a generic chemotherapy agent. ANX-530 is designed to reduce the incidence and severity of vein irritation from intravenous-delivery of vinorelbine tartrate. Vinorelbine tartrate works by disrupting microtubule formation and is a member of the vinca alkaloid class of antineoplastic agents. Vinorelbine is indicated as a single agent or in combination with cisplatin for treatment of advanced non-small cell lung cancer and has also shown activity in breast, ovarian, and other cancers.

About Section 505(b)(2)

Section 505(b)(2) of the
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
7. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
8. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
9. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
10. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  Diplomat, the nation,s largest independent specialty ... to the Board of Directors on September 15, ... also serve as chair of the Audit Committee. ... accounting, financial, compliance and operating experience in the health ... as chief financial officer, chief operating officer and secretary ...
(Date:9/19/2014)... According to market research ... Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical ... & Geography - Global Trends & Forecast to ... lyophilization market on the basis of various types, ... the market size of each of these segments ...
(Date:9/19/2014)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... ® in the U.S. and XIAPEX ® in ... , will present a corporate overview at the 21 st ... The presentation will take place on Friday, September ... Hotel in New York, NY . A ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... a quadriplegic triathlete, has been named spokesperson for National ... with disabilities to live active, mobile lifestyles. The goal ... well as the many other transportation solutions that can ... those with disabilities. Savicki is a proud partner along ...
... In the Middle East and North Africa ... MENA region are among the top 10 globally with the ... Bahrain, Egypt, Kuwait, Oman and Saudi Arabia. The region spends ... its total health care expenditure and expenditure averages as high ...
Cached Medicine Technology:69-Time Gold Medalist and Multi-Sport Wheelchair Athlete Named Spokesperson for National Mobility Awareness Month 269-Time Gold Medalist and Multi-Sport Wheelchair Athlete Named Spokesperson for National Mobility Awareness Month 3Meeting of the Region's Top Diabetes Experts in Dubai this March 2
(Date:9/20/2014)... New York, New York (PRWEB) September 20, 2014 ... of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in ... notes that yet another insurer has announced plans ... a statement posted on its website last month, ... such procedures effective November 1, 2014. The insurer ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), a ... website. The new site provides the latest reviews ... customers. Here, people can find a lot of ... it has recommended some excellent web hosting suppliers ... great web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ), ...
(Date:9/20/2014)... dentists have advised their patients against drinking coffee and wine. ... that advice and changing his stance after considering two recent ... oral health. “There’s good news and great news,” says Dr. ... protecting against gum disease, and red wine can help fight ... the September 2014 issue of Boston University School of ...
(Date:9/20/2014)... Recently, UWDress.com, an innovative company that provides ... outfits, has launched a special offer for its brand ... popular among worldwide clients. Now, all the company’s new ... on its website. , Additionally, the firm also ... world. Great custom made items can be ordered at ...
(Date:9/20/2014)... New York, NY (PRWEB) September 20, 2014 ... million of their customers may have had their credit card ... late last year, spawning a slew of headline articles ... but those weren’t the only eye opening numbers. , ... numbers were stolen, almost like it’s a way to score ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5
... , SALT LAKE CITY, Aug. 4 RIESTER creative from ... National Drug Control Policy (ONDCP) to become a key resource to states ... other approaches combating meth addiction, the End Meth Now campaign inspires hope ... , , "We,ve had the privilege of working ...
... , , COLD SPRING ... the world,s first hand-held, non-contact vein illumination device, announced today that ... to commence European sales of AccuVein,s AV300. , , ... an important step in bringing this beneficial device to healthcare practitioners ...
... lab studies, intermittent calorie restriction led to dramatic decrease ... Periodically cutting calories may lower the risk of developing ... new study published in Cancer Prevention Research . ... tumors were put on different diets: unlimited eating, intermittently ...
... Effort aims to create an international Network of ... co-operative and collaborative approach to combating the problem of health ... Aug. 4 The National Health Care Anti-Fraud Association (NHCAA) ... with two like-minded organizations--the Canadian Health Care Anti-fraud Association (CHCAA) ...
... PALM CITY, Fla., Aug. 4 Connectyx Technologies ... that the Company has formed a partnership with InstantAmber, a ... agreement will enable InstantAmber to offer the MedFlash(TM) product to ... tool that gives parents the ability to keep up to ...
... , , , ... , ALISO VIEJO, Calif., Aug. 4 Valeant Pharmaceuticals International ... 2009. , , "The second quarter once again demonstrated ... and chief executive officer. "We delivered sales and earnings growth at ...
Cached Medicine News:Health News:Office of National Drug Control Policy Taps RIESTER creative for Use in National Anti-Meth Campaign 2Health News:AccuVein Vein Illuminator Receives European CE Mark 2Health News:Periodic Dieting May Cut Breast Cancer Risk 2Health News:The National Health Care Anti-Fraud Association Signs Memorandum of Understanding With Canadian and European Anti-Fraud Organizations 2Health News:The National Health Care Anti-Fraud Association Signs Memorandum of Understanding With Canadian and European Anti-Fraud Organizations 3Health News:Connectyx Partners with InstantAmber, a Leader in Child Safety and Missing Children Awareness 2Health News:Connectyx Partners with InstantAmber, a Leader in Child Safety and Missing Children Awareness 3Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 2Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 3Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 4Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 5Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 6Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 7Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 8Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 9Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 10Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 11Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 12Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 13Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 14Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 15Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 16Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 17Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 18Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 19Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 20Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 21Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 22Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 23
Shandon Plastic Slide Boxes...
Shandon Cardboard Slide Folders...
... The new Propaq LT is the ... environment--combining the basic parameters of continuous vital ... new design, making it perfect for just ... place. , Light enough to clip on ...
Exxcel Soft ePTFE vascular graft, designed for exceptional kink resistance and crush resistance, maintains a Soft touch for easier handling during peripheral vascular bypass procedures and vascular a...
Medicine Products: